Fracture protection from menopausal hormone therapy vanishes within a year of stopping, with a temporary spike in fracture risk afterward.
- Menopausal hormone therapy lowers bone fracture risk during use
- Fracture protection fades completely within one year of stopping therapy
- Risk rises temporarily after discontinuation before declining over time
Bone fracture protection offered by menopausal hormone therapy vanishes within one year after the treatment ends (1✔ ✔Trusted Source
Discontinuation of menopausal hormone therapy and risk of fracture: nested case-control studies using routinely collected primary care data
).
Published in Lancet Healthy Longevity, experts at the School of Medicine, University of Nottingham, found that once women stop hormone therapy, they experience a temporary increase in fracture risk compared to those who never used it. Over time, this elevated risk reduces and eventually falls below that of never-users.
Advertisement
Fracture Risk Pattern Post Hormone Therapy
This investigation, supported by the National Institute for Health and Care Research SPCR, examined the biological effects of menopause, particularly the drop in estrogen levels that can lead to both physical and psychological symptoms.
Estrogen deficiency is also known to weaken bones with age. While the hormone component in therapy is recognized for reducing fracture risks during treatment, there are concerns tied to prolonged use, such as heightened risks of breast cancer and blood clots. As a result, prolonged therapy is generally discouraged.
Because of this, it’s important for patients and clinicians to understand the lasting impact of the treatment once it’s discontinued. Previous data was limited and often inconsistent, mostly covering the initial years after stopping hormone use.
Advertisement
Analysis of 6 Million Women’s Health Records
This new analysis examined data from six million women across 2,000 general practices in the United Kingdom, allowing for follow-up periods of up to 25 years. Researchers matched women who had a first-time fracture with others of the same age and from the same practice who had no record of fractures. The team then compared the use of hormone therapy among these groups.
Dr. Yana Vinogradova, lead author and part of the Centre for Academic Primary Care at the School of Medicine, explained that women actively using hormone therapy showed reduced fracture risk. Notably, the risk patterns shifted once therapy was stopped.
Fracture Risk Timeline and Implications
Dr. Vinogradova outlined that the protective effect fades entirely about one year after discontinuation. Then, fracture risk rises and peaks around three years later. After roughly a decade, the risk drops to match that of women who never used hormone therapy and then continues to decline beyond that.
This trend was consistent across all types of menopausal hormonal treatments, although the extent of increased risk depended on the type of therapy and how long it had been used.
Supporting Treatment Decisions and…
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We 5guruayurveda.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on. For any glitch kindly connect at 5guruayurveda.com
